[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023283642A3 - Pan-human coronavirus concatemeric vaccines - Google Patents

Pan-human coronavirus concatemeric vaccines Download PDF

Info

Publication number
WO2023283642A3
WO2023283642A3 PCT/US2022/073564 US2022073564W WO2023283642A3 WO 2023283642 A3 WO2023283642 A3 WO 2023283642A3 US 2022073564 W US2022073564 W US 2022073564W WO 2023283642 A3 WO2023283642 A3 WO 2023283642A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
pan
concatemeric
human coronavirus
coronavirus
Prior art date
Application number
PCT/US2022/073564
Other languages
French (fr)
Other versions
WO2023283642A8 (en
WO2023283642A2 (en
Inventor
Guillaume Stewart-Jones
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of WO2023283642A2 publication Critical patent/WO2023283642A2/en
Publication of WO2023283642A3 publication Critical patent/WO2023283642A3/en
Publication of WO2023283642A8 publication Critical patent/WO2023283642A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure relates to pan-human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
PCT/US2022/073564 2021-07-09 2022-07-08 Pan-human coronavirus concatemeric vaccines WO2023283642A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163220346P 2021-07-09 2021-07-09
US63/220,346 2021-07-09
US202263321952P 2022-03-21 2022-03-21
US63/321,952 2022-03-21

Publications (3)

Publication Number Publication Date
WO2023283642A2 WO2023283642A2 (en) 2023-01-12
WO2023283642A3 true WO2023283642A3 (en) 2023-02-23
WO2023283642A8 WO2023283642A8 (en) 2024-01-18

Family

ID=84802127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/073564 WO2023283642A2 (en) 2021-07-09 2022-07-08 Pan-human coronavirus concatemeric vaccines

Country Status (1)

Country Link
WO (1) WO2023283642A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
MA49914A (en) 2017-08-18 2021-04-21 Modernatx Inc HPLC ANALYTICAL PROCESSES
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
WO2023092069A1 (en) * 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190062785A1 (en) * 2016-04-04 2019-02-28 The United States of America, as represented by the Secretary, Department of Health & Human Servic Multivalent vaccines for rabies virus and coronoviruses
US20190211065A1 (en) * 2017-02-16 2019-07-11 Modernatx, Inc. High potency immunogenic compositions
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine
WO2021178971A1 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
WO2021211749A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Multi-epitope pan-coronavirus vaccine compositions
WO2021239880A1 (en) * 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2022093895A1 (en) * 2020-10-27 2022-05-05 The University Of North Carolina At Chapel Hill Chimeric coronavirus s protein compositions and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190062785A1 (en) * 2016-04-04 2019-02-28 The United States of America, as represented by the Secretary, Department of Health & Human Servic Multivalent vaccines for rabies virus and coronoviruses
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine
US20190211065A1 (en) * 2017-02-16 2019-07-11 Modernatx, Inc. High potency immunogenic compositions
WO2021178971A1 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
WO2021211749A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Multi-epitope pan-coronavirus vaccine compositions
WO2021239880A1 (en) * 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2022093895A1 (en) * 2020-10-27 2022-05-05 The University Of North Carolina At Chapel Hill Chimeric coronavirus s protein compositions and methods of use

Also Published As

Publication number Publication date
WO2023283642A8 (en) 2024-01-18
WO2023283642A2 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
WO2023283642A8 (en) Pan-human coronavirus concatemeric vaccines
MX2022009280A (en) Coronavirus rna vaccines.
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
WO2021155243A8 (en) Respiratory virus immunizing compositions
WO2017070616A3 (en) Sexually transmitted disease vaccines
PH12018500855A1 (en) Herpes simplex virus vaccine
TW200630478A (en) Processes for preparation of oil compositions
WO2007024941A3 (en) Polyvalent vaccine
WO2002006213A3 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
WO2019147749A3 (en) Stabilized rsv f proteins and uses thereof
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
ZA202306901B (en) Ionizable lipids
WO2019147743A8 (en) Structure-guided chemical modification of guide rna and its applications
MX2023007319A (en) Nucleic acid vaccines.
WO2022137128A3 (en) Self-amplifying messenger rna
WO2023114932A3 (en) Subtilisin variants and uses thereof
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
WO2021231263A3 (en) Nucleic acid amplification methods
EA200500775A1 (en) EFFECTS OF CARBAMIC ACID THAT HAVE ANTICHOLINERGIC ACTION
WO2002101063A3 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
DE60325838D1 (en) IMIDAZOQUINOLINAMINE AS ADJUVANTIES FOR HIV DNA VACCINE
WO2004084935A3 (en) Francisella strain for live vaccine
WO2023104114A8 (en) Rna formulations and lipids
EP2198828A3 (en) Dilute structured compositions comprising a branched fatty alcohol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22838605

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22838605

Country of ref document: EP

Kind code of ref document: A2